Teva, Bausch & Lomb receive tentative ANDA approval for generic versions of Rogaine.
This article was originally published in The Rose Sheet
TEVA, BAUSCH & LOMB RECEIVE TENTATIVE APPROVAL TO MARKET GENERIC ROGAINE beginning on Feb. 13, when Pharmacia & Upjohn's patent for the topical minoxidil 2% hair loss treatment expires. Teva's generic subsidiary Lemmon received the first tentative abbreviated new drug approval (ANDA) for topical minoxidil on Dec. 15; Bausch & Lomb Pharmaceuticals received tentative approval on Dec. 22.
You may also be interested in...
With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program
Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle
Weekly Trademark Review